Status:
COMPLETED
A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
35-70 years
Phase:
PHASE1
Brief Summary
The purposes of this study are to determine the safety and side effects of LY3000328, to determine how well the body will tolerate LY3000328, and to determine how long LY3000328 remains in the body.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Are overtly healthy males or females, as determined by medical history and physical examination
Exclusion
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2012
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01515358
Start Date
February 1 2012
End Date
May 1 2012
Last Update
May 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore, 117597